Kristen Williams
CIK 1296965 · View on SEC EDGAR ↗
Insider
First SEC filing: June 5, 2026 · Latest: June 5, 2026
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
1 sells (S)
Net:
$-228,468
+ 71 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
71 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 3, 2026 | PCRX | S | 10,259 | $22.27 | $228,468 | 167,062 | — | — | 8.1% (price as of 2026-08-20) |
| June 4, 2025 | PCRX | S | 14,376 | $26.24 | $377,226 | 161,574 Direct | -8.17% | Disposed | -8.2% (price as of 2026-08-20) |
| June 13, 2024 | PCRX | S 10b5-1 | 7,452 | $28.38 | $211,488 | 102,912 Direct | -6.75% | Disposed | -15.1% (price as of 2026-08-20) |
| June 14, 2023 | PCRX | S 10b5-1 | 6,467 | $37.03 | $239,473 | 25,375 Direct | -20.31% | Disposed | -35.0% (price as of 2026-08-20) |
| June 7, 2023 | PCRX | S | 1,357 | $37.86 | $51,376 | 20,892 Direct | -6.10% | Disposed | -36.4% (price as of 2026-08-20) |
| June 6, 2023 | PCRX | S | 1,301 | $38.99 | $50,726 | 22,249 Direct | -5.52% | Disposed | -38.2% (price as of 2026-08-20) |
| June 7, 2022 | PCRX | S 10b5-1 | 4,649 | $59.51 | $276,662 | 13,650 Direct | -25.41% | Disposed | -59.5% (price as of 2026-08-20) |
| June 6, 2022 | PCRX | S 10b5-1 | 3,969 | $61.37 | $243,578 | 18,299 Direct | -17.82% | Disposed | -60.8% (price as of 2026-08-20) |
| March 21, 2022 | PCRX | S 10b5-1 | 7,253 | $72.67 | $527,076 | 22,268 Direct | -24.57% | Disposed | -66.9% (price as of 2026-08-20) |
| Feb. 25, 2022 | PCRX | S 10b5-1 | 50 | $65.00 | $3,250 | 24,268 Direct | -0.21% | Disposed | -62.9% (price as of 2026-08-20) |
| Feb. 25, 2022 | PCRX | S 10b5-1 | 2,000 | $67.07 | $134,140 | 22,268 Direct | -8.24% | Disposed | -64.1% (price as of 2026-08-20) |
| Feb. 16, 2022 | PCRX | S 10b5-1 | 10 | $65.00 | $650 | 22,268 Direct | -0.04% | Disposed | -62.9% (price as of 2026-08-20) |
| Feb. 10, 2022 | PCRX | S 10b5-1 | 800 | $65.18 | $52,144 | 22,268 Direct | -3.47% | Disposed | -63.0% (price as of 2026-08-20) |
| Feb. 4, 2022 | PCRX | S 10b5-1 | 1,000 | $65.18 | $65,180 | 22,268 Direct | -4.30% | Disposed | -63.0% (price as of 2026-08-20) |
| Jan. 21, 2022 | PCRX | S 10b5-1 | 200 | $65.41 | $13,082 | 22,268 Direct | -0.89% | Disposed | -63.2% (price as of 2026-08-20) |
| Jan. 19, 2022 | PCRX | S 10b5-1 | 2,199 | $65.51 | $144,056 | 22,268 Direct | -8.99% | Disposed | -63.2% (price as of 2026-08-20) |
| Jan. 18, 2022 | PCRX | S 10b5-1 | 400 | $66.14 | $26,456 | 22,268 Direct | -1.76% | Disposed | -63.6% (price as of 2026-08-20) |
| Jan. 18, 2022 | PCRX | S 10b5-1 | 23,040 | $65.24 | $1,503,130 | 22,668 Direct | -50.41% | Disposed | -63.1% (price as of 2026-08-20) |
| June 10, 2021 | PCRX | S 10b5-1 | 4,842 | $59.43 | $287,760 | 23,115 Direct | -17.32% | Disposed | -59.5% (price as of 2026-08-20) |
| June 10, 2021 | PCRX | S 10b5-1 | 847 | $60.57 | $51,303 | 22,268 Direct | -3.66% | Disposed | -60.2% (price as of 2026-08-20) |
| June 4, 2021 | PCRX | S | 3,930 | $61.04 | $239,887 | 20,957 Direct | -15.79% | Disposed | -60.5% (price as of 2026-08-20) |
| April 13, 2021 | PCRX | S 10b5-1 | 7,030 | $68.11 | $478,813 | 24,887 Direct | -22.03% | Disposed | -64.6% (price as of 2026-08-20) |
| April 13, 2021 | PCRX | S 10b5-1 | 14,793 | $66.40 | $982,255 | 31,917 Direct | -31.67% | Disposed | -63.7% (price as of 2026-08-20) |
| Sept. 17, 2020 | PCRX | S 10b5-1 | 3,200 | $60.22 | $192,704 | 24,887 Direct | -11.39% | Disposed | -60.0% (price as of 2026-08-20) |
| Sept. 17, 2020 | PCRX | S 10b5-1 | 24,671 | $59.77 | $1,474,586 | 28,087 Direct | -46.76% | Disposed | -59.7% (price as of 2026-08-20) |
| Sept. 16, 2020 | PCRX | S 10b5-1 | 21,244 | $60.33 | $1,281,651 | 24,887 Direct | -46.05% | Disposed | -60.1% (price as of 2026-08-20) |
| Sept. 16, 2020 | PCRX | S 10b5-1 | 6,609 | $59.54 | $393,500 | 46,131 Direct | -12.53% | Disposed | -59.5% (price as of 2026-08-20) |
| Sept. 15, 2020 | PCRX | S 10b5-1 | 13,231 | $59.80 | $791,214 | 24,887 Direct | -34.71% | Disposed | -59.7% (price as of 2026-08-20) |
| Sept. 15, 2020 | PCRX | S 10b5-1 | 14,622 | $59.01 | $862,844 | 38,118 Direct | -27.72% | Disposed | -59.2% (price as of 2026-08-20) |
Showing latest 100 of 140 transactions
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 14, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock (27,500) | $38.74 | June 14, 2033 | 27,500 | Acquired |
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (24,800) | $59.39 | June 8, 2032 | 24,800 | Acquired |
| March 21, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (2,188) | $47.65 | June 9, 2030 | 2,188 | Disposed |
| March 21, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (2,112) | $43.54 | June 5, 2029 | 2,112 | Disposed |
| March 21, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (2,953) | $38.35 | June 13, 2028 | 2,953 | Disposed |
| Feb. 25, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (2,050) | $38.35 | June 13, 2028 | 2,050 | Disposed |
| Feb. 16, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (10) | $38.35 | June 13, 2028 | 10 | Disposed |
| Feb. 10, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (800) | $38.35 | June 13, 2028 | 800 | Disposed |
| Feb. 4, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (1,000) | $38.35 | June 13, 2028 | 1,000 | Disposed |
| Jan. 21, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (200) | $38.35 | June 13, 2028 | 200 | Disposed |
| Jan. 19, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (2,199) | $38.35 | June 13, 2028 | 2,199 | Disposed |
| Jan. 18, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (13,127) | $47.65 | June 9, 2030 | 13,127 | Disposed |
| Jan. 18, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (6,338) | $43.54 | June 5, 2029 | 6,338 | Disposed |
| Jan. 18, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (2,600) | $38.35 | June 13, 2028 | 2,600 | Disposed |
| Jan. 18, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock (1,375) | $44.20 | June 14, 2027 | 1,375 | Disposed |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock (17,500) | $60.96 | June 9, 2031 | 17,500 | Acquired |
| April 13, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock (6,339) | $43.54 | June 5, 2029 | 6,339 | Disposed |
| April 13, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock (8,859) | $38.35 | June 13, 2028 | 8,859 | Disposed |
| April 13, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock (4,125) | $44.20 | June 14, 2027 | 4,125 | Disposed |
| April 13, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock (2,500) | $32.35 | Dec. 7, 2026 | 2,500 | Disposed |
| Sept. 17, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (2,819) | $43.54 | June 5, 2029 | 2,819 | Disposed |
| Sept. 17, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (7,878) | $38.35 | June 13, 2028 | 7,878 | Disposed |
| Sept. 17, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,502) | $44.20 | June 14, 2027 | 5,502 | Disposed |
| Sept. 17, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,836) | $32.35 | Dec. 7, 2026 | 5,836 | Disposed |
| Sept. 17, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,836) | $40.34 | June 15, 2026 | 5,836 | Disposed |
| Sept. 16, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (2,816) | $43.54 | June 5, 2029 | 2,816 | Disposed |
| Sept. 16, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (7,874) | $38.35 | June 13, 2028 | 7,874 | Disposed |
| Sept. 16, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,499) | $44.20 | June 14, 2027 | 5,499 | Disposed |
| Sept. 16, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,832) | $32.35 | Dec. 7, 2026 | 5,832 | Disposed |
| Sept. 16, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,832) | $40.34 | June 15, 2026 | 5,832 | Disposed |
| Sept. 15, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (2,816) | $43.54 | June 5, 2029 | 2,816 | Disposed |
| Sept. 15, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (7,874) | $38.35 | June 13, 2028 | 7,874 | Disposed |
| Sept. 15, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,499) | $44.20 | June 14, 2027 | 5,499 | Disposed |
| Sept. 15, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,832) | $32.35 | Dec. 7, 2026 | 5,832 | Disposed |
| Sept. 15, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (5,832) | $40.34 | June 15, 2026 | 5,832 | Disposed |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock (35,000) | $47.65 | June 9, 2030 | 35,000 | Acquired |
| June 5, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock (33,800) | $43.54 | June 5, 2029 | 33,800 | Acquired |
| June 13, 2018 | PCRX | Stock Option (Right to Buy) | Common Stock (47,250) | $38.35 | June 13, 2028 | 47,250 | Acquired |
| Nov. 17, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (7,857) | $25.37 | March 5, 2023 | 7,857 | Disposed |
| Nov. 16, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (2,143) | $25.37 | March 5, 2023 | 2,143 | Disposed |
| June 14, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (22,000) | $44.20 | June 14, 2027 | 22,000 | Acquired |
| May 15, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (11,979) | $10.81 | June 5, 2022 | 11,979 | Disposed |
| May 15, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (5,937) | $10.52 | March 2, 2022 | 5,937 | Disposed |
| May 15, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock (3,125) | $9.25 | Oct. 19, 2021 | 3,125 | Disposed |
| Dec. 7, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock (20,000) | $32.35 | Dec. 7, 2026 | 20,000 | Acquired |
| June 15, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock (17,500) | $40.34 | June 15, 2026 | 17,500 | Acquired |
| June 3, 2015 | PCRX | Stock Option (Right to Buy) | Common Stock (15,000) | $79.43 | June 3, 2025 | 15,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Oct. 14, 2014 | PCRX | Stock Option (Right to Buy)→ Common Stock (3,125) | 3,125 | Direct |
| Oct. 14, 2014 | PCRX | Stock Option (Right to Buy)→ Common Stock (5,937) | 5,937 | Direct |
| Oct. 14, 2014 | PCRX | Stock Option (Right to Buy)→ Common Stock (11,979) | 11,979 | Direct |
| Oct. 14, 2014 | PCRX | Stock Option (Right to Buy)→ Common Stock (10,000) | 10,000 | Direct |
| Oct. 14, 2014 | PCRX | Stock Option (Right to Buy)→ Common Stock (40,000) | 40,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
PCRX
Chief Administrative Officer and Secretary| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $501,018 | $225,900 | $424,203 | $438,138 | — | — | $11,602 | $1,600,861 |
| 2022 | $457,046 | $330,400 | $587,961 | $621,240 | — | — | $12,188 | $2,008,835 |
| 2019 | $479,231 | $225,000 | $243,824 | $720,919 | — | — | $23,743 | $1,692,717 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.